Pfizer Australia is fined for misleading promotion of celecoxibBMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7502.1230-b (Published 26 May 2005) Cite this as: BMJ 2005;330:1230
- Bob Burton
Pfizer Australia has been fined for breaching the drug industry's own marketing code of conduct over a letter it sent to health professionals defending the safety of celecoxib (Celebrex) after the recall of rofecoxib (Vioxx) last year.
In a letter that Pfizer sent out in October the company said that “the cardiovascular safety profile of Celebrex has been extensively studied” and that “the data do not indicate significant cardiovascular safety concerns with Celebrex.” Pfizer wrote of the study on the long term safety of celecoxib in arthritis that “there was no increase in serious cardiovascular thromboembolic events in patients on Celebrex who were or …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial